Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

11. Mai 2020 16:01 ET | Quelle: Liquidia Technologies, Inc.

Liquidia Reports First Quarter 2020 Financial Results and Provides Corporate Update

Received FDA Acceptance of LIQ861 NDA for ReviewReported Final Safety and Tolerability Results for LIQ861 Inspire TrialManagement to Host Webcast and Conference Call Today at 4:30p.m. ET ...
06. Mai 2020 18:30 ET | Quelle: Liquidia Technologies, Inc.

Liquidia to Report First Quarter 2020 Financial Results and Provide Corporate Update on May 11, 2020

RESEARCH TRIANGLE PARK, N.C., May 06, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA), a late-stage clinical biopharmaceutical company focused on the development and...
30. April 2020 07:30 ET | Quelle: Liquidia Technologies, Inc.

Liquidia Releases Final LIQ861 Results from Pivotal Phase 3 INSPIRE Study in Patients with Pulmonary Arterial Hypertension

RESEARCH TRIANGLE PARK, N.C., April 30, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and...
09. April 2020 07:30 ET | Quelle: Liquidia Technologies, Inc.

Liquidia to Present at the 19th Annual Needham Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., April 09, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and...
08. April 2020 07:45 ET | Quelle: Liquidia Technologies, Inc.

Liquidia Announces FDA Acceptance of New Drug Application for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension

RESEARCH TRIANGLE PARK, N.C., April 08, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and...
11. März 2020 07:00 ET | Quelle: Liquidia Technologies, Inc.

Liquidia Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update

Submitted New Drug Application (NDA) for LIQ861 in January 2020 Management to Host Webcast and Conference Call Today at 8:00 a.m. ET RESEARCH TRIANGLE PARK, N.C., March 11, 2020 (GLOBE NEWSWIRE) --...
26. Februar 2020 16:30 ET | Quelle: Liquidia Technologies, Inc.

Liquidia to Report 2019 Financial Results and Provide Corporate Update on March 11, 2020

RESEARCH TRIANGLE PARK, N.C., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development of...
26. Februar 2020 16:30 ET | Quelle: Liquidia Technologies, Inc.

Liquidia to Present at Cowen 40th Annual Health Care Conference

RESEARCH TRIANGLE PARK, N.C., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development of...
27. Januar 2020 08:00 ET | Quelle: Liquidia Technologies, Inc.

Liquidia Submits New Drug Application for LIQ861 (treprostinil) inhalation powder to U.S. Food and Drug Administration for the Treatment of Pulmonary Arterial Hypertension (PAH)

RESEARCH TRIANGLE PARK, N.C., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development of...
24. Januar 2020 09:00 ET | Quelle: Liquidia Technologies, Inc.

Liquidia Announces Poster Presentation at the 14th Annual World Congress of the Pulmonary Vascular Research Institute (PVRI)

RESEARCH TRIANGLE PARK, N.C., Jan. 24, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and...

Vorherige Seite

Nächste Seite